Related Experiment Video

Updated: May 28, 2026

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
08:22

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene

Published on: September 16, 2019

Fragile X syndrome and targeted treatment trials

Randi Hagerman1, Julie Lauterborn, Jacky Au

  • 1Department of Pediatrics, University of California, Sacramento, CA, USA. randi.hagerman@ucdmc.ucdavis.edu

Results and Problems in Cell Differentiation
|October 20, 2011
PubMed

Insights

New research identifies potential treatments for fragile X syndrome (FXS). Animal models show that targeting metabotropic glutamate receptors and GABA pathways can reverse key neurobiological deficits, offering hope for FXS and autism.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Fragile X syndrome (FXS) is caused by the absence of Fragile X Mental Retardation Protein (FMRP).
  • FMRP deficiency leads to gene dysregulation, neurotransmission imbalances, and synaptic plasticity deficits.
  • Animal models, like the fragile X knockout mouse, closely mimic human FXS phenotypes.

Purpose of the Study:

  • To explore novel therapeutic targets for fragile X syndrome.
  • To review the efficacy of potential pharmacological and educational interventions.
  • To assess the translational potential of FXS treatments for other neurodevelopmental disorders.

Main Methods:

  • Utilizing fragile X knockout mouse and fly models to study FXS.
  • Investigating the effects of metabotropic glutamate receptor (mGluR) blockers.
  • Examining the impact of gamma amino-butyric acid (GABA) agonists on cellular and behavioral phenotypes.

Main Results:

  • mGluR blockers and GABA agonists demonstrated efficacy in reversing cellular and behavioral deficits in models.
  • These interventions helped restore proper brain connectivity in affected animal models.
  • Targeted treatments show preliminary success in mitigating neurobiological abnormalities.

Conclusions:

  • Targeted pharmacological and educational interventions show promise for FXS treatment.
  • Restoring FMRP function or compensating for its absence is a key therapeutic strategy.
  • Findings suggest potential applications for treating autism and other neurodevelopmental disorders.

More Related Videos

Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation11:10

Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation

Published on: July 6, 2022

TMS: Using the Theta-Burst Protocol to Explore Mechanism of Plasticity in Individuals with Fragile X Syndrome and Autism10:58

TMS: Using the Theta-Burst Protocol to Explore Mechanism of Plasticity in Individuals with Fragile X Syndrome and Autism

Published on: December 28, 2010

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Sex-linked Disorders01:43

Sex-linked Disorders

Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.